Xoma completes enrollment of Phase III

XOMA and partner Genentech (DNA) completed enrollment of more than 1,000 patients in two Phase III trials in the U.S. and Canada of anti-CD11a (hu1124) humanized monoclonal antibody to treat moderate ...